Elecoglipron, an oral daily GLP-1, confers glucose, weight reduction in phase 2 studies

NEW ORLEANS — A novel oral small-molecule GLP-1 receptor agonist demonstrated reductions in HbA1c and body weight among individuals with type 2 diabetes and obesity.Researchers presented results from the phase 2 SOLSTICE and VISTA studies at the American Diabetes Association Scientific Sessions. Both studies evaluated efficacy, safety and tolerability of elecoglipron (AstraZeneca); SOLSTICE